Seth Pollack, MD: We Just Need to Keep Knocking
Years Funded: 2018-2020
Class I and Class II Restricted TCRs following Stereotactic Body Radiotherapy
Determined to produce more consistent, complete and durable responses to T cell therapies for solid tumors, Seth Pollack, MD, and his team at Fred Hutchinson Cancer Research Center (Seattle, WA) are developing a first-ever combination of two types of genetically engineered T cells (CD4+ and CD8+), each with unique receptors. With assistance from precision radiation, it’s hoped the cells will recognize and demolish sarcomas.